# Yasuo Ohashi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yasuo-ohashi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 42,227 |
| Field | Breast Cancer Treatment Studies |
| h-index | 91 |
| i10-index | 447 |
| Last Known Institution | Chuo University |
| OpenAlex ID | https://openalex.org/A5090955736 |
| ORCID iD | 0000-0003-3177-4474 |
| Works | 851 |

## Researcher papers

Showing 12 of 15.

- [Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine](https://scholariq.org/papers/adjuvant-chemotherapy-for-gastric-cancer-with-s-1-an-oral-fluoropyrimidine/)
- [Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials](https://scholariq.org/papers/statins-and-risk-of-incident-diabetes-a-collaborative-meta-analysis-of/)
- [Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy](https://scholariq.org/papers/adjuvant-capecitabine-for-breast-cancer-after-preoperative-chemotherapy/)
- [Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer](https://scholariq.org/papers/five-year-outcomes-of-a-randomized-phase-iii-trial-comparing-adjuvant/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)](https://scholariq.org/papers/adjuvant-chemotherapy-of-s-1-versus-gemcitabine-for-resected-pancreatic-cancer-a/)
- [Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial](https://scholariq.org/papers/primary-prevention-of-cardiovascular-disease-with-pravastatin-in-japan-mega/)
- [Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial](https://scholariq.org/papers/adoptive-immunotherapy-to-lower-postsurgical-recurrence-rates-of-hepatocellular/)
- [Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan](https://scholariq.org/papers/randomized-phase-iii-study-of-cisplatin-plus-irinotecan-versus-carboplatin-plus/)
- [Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study](https://scholariq.org/papers/randomized-phase-iii-study-of-gemcitabine-plus-s-1-s-1-alone-or-gemcitabine/)
- [Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial](https://scholariq.org/papers/rituximab-for-childhood-onset-complicated-frequently-relapsing-nephrotic/)
- [Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial](https://scholariq.org/papers/febuxostat-therapy-for-patients-with-stage-3-ckd-and-asymptomatic-hyperuricemia/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Researcher university

- [Chuo University](https://scholariq.org/institutions/chuo-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.